ValiRx Plc - VAL201 Clinical Trial Full Data Results

Dr Suzy Dilly, Chief Executive Officer discusses the VAL201 clinical trial results. The full dataset confirms VAL201 is a safe and well-tolerated drug candidate, demonstrating the potential of VAL201 for further development towards a treatment for patients with prostate cancer.

Suzanne Dilly
Chief Executive Officer

Company Events - VALIRX PLC